← Retour à la une
États-Unis · Plateformes & données · Yahoo Finance

Evaxion (EVAX) Q3 2026 Earnings Call Transcript

Publié par Yahoo Finance · États-Unis il y a 8 h
Evaxion (EVAX) Q3 2026 Earnings Call Transcript
Yahoo Finance

Résumé détaillé

Head of Investor Relations and Communications - Mads Kronborg Need a quote from a Motley Fool analyst? Email pr@fool.com ...

Operator: Good day, and thank you for standing by. Welcome to the Evaxion Strategy and Business Update and Third Quarter 2026 Financial Results Webcast and Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star, one, and one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star, one, and one again. Please be advised that today's conference is being recorded.

Helen Tayton-Martin: Thank you, and good morning and welcome, to everyone to Evaxion's Strategy and Business Update for Q3. I'm Helen Tayton-Martin. I'm the Chief Executive Officer of Evaxion, and I'm joined today on the call by Birgitte Rønø, our Chief Scientific Officer and Chief Operating Officer, and Thomas Schmidt, Chief Financial Officer, Mads Kronborg, our Head of Investor Relations and Communications.

Thomas will take you through the financial results for the quarter before we wrap up with some concluding remarks and take questions. As a reminder, we may make forward-looking statements during today's call, and in that context, I would refer you to our most recent filed statements. Turning to the first agenda point, our strategy update. Put very simply, Evaxion is now refocusing all of its own resources in the application of our AI-Immunology platform towards our oncology portfolio.

With Moderna's recent phase III groundbreaking data validating personalized cancer vaccines as truly capable of delivering meaningful clinical benefit in adjuvant melanoma, we have been proud and excited to share our own phase II three-year clinical data in recent weeks, in which patients with metastatic melanoma, where we used our AI-Immunology platform to predict high-quality and relevant antigens for patients, which was correlated with high precision in terms of the immune response…

In…

Début de l'article, extrait de Yahoo Finance. Pour lire la suite, ouvrez l'article chez le média.

Lire l'article complet sur Yahoo Finance Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finance.yahoo.com)

À lire aussi